Skip to main content
. 2023 Feb 28;58(5):567–580. doi: 10.1038/s41409-023-01946-0

Fig. 3. Cumulative incidence of breakthrough SARS-CoV-2 infection.

Fig. 3

Cumulative incidence of SARS-CoV-2 infection in allo-HSCT according to a cell therapy procedure, b use of immunosuppression at the time of first vaccine dose and c conditioning intensity.